
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tempol
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
Details : Tempol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Tempol
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MBM-01
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : University of Texas Health Science Center at Houston
Deal Size : Inapplicable
Deal Type : Inapplicable
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia
Details : MBM-01 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ataxia Telangiectasia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 14, 2021
Lead Product(s) : MBM-01
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : University of Texas Health Science Center at Houston
Deal Size : Inapplicable
Deal Type : Inapplicable

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
Details : MBM-02 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2021

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
Details : MBM-02 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2021

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Adamis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Adamis Pharmaceuticals Announces License to Commercialize Tempol
Details : The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.
Product Name : Tempol
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 15, 2020
Lead Product(s) : Tempol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Adamis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tempol
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
Details : Tempol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 07, 2020
Lead Product(s) : Tempol
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tempol
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
Details : Tempol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mucositis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2018
Lead Product(s) : Tempol
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All